<p>The invention provides PYGM as a biomarker for PPARa modulators. The invention relates to the identification of a biomarker or a set of biomarkers or a combination of molecular and clinical markers to monitor or identify or quantify a treatment with a PPARa modulator or a combination of one or more PPARa modulators with other pharmacological compounds.</p>
